Though the early integration of mesenchymal stem cells (MSCs) into tumor-associated stroma of cancer has been demonstrated, the functional contributions and underlying mechanisms of these cells to tumor growth and angiogenesis remain to be clarified. Using a xenograft model, human colorectal cancer cells, MSCs, and their cell mixture were introduced to a subcutaneous site of immunodeficient mice. The tumor growth rate and angiogenesis of each transplantation was then compared. We demonstrate that a variety of colorectal cancer cells, when mixed with otherwise non-tumorigenic MSCs, increase the tumor growth rate and angiogenesis more than that when mixed with carcinoma-associated fibroblasts or normal colonic fibroblasts. The secretion of interleukin-6 (IL-6) from MSCs increases the secretion of endothelin-1 (ET-1) in cancer cells, which induces the activation of Akt and ERK in endothelial cells, thereby enhancing their capacities for recruitment and angiogenesis to tumor. The IL-6/ET-1/Akt or ERK pathway of tumor-stroma interaction can be targeted by an antibody against IL-6 or Lentiviral-mediated RNAi against IL-6 in MSCs, by inhibition or knockdown of ET-1 in cancer cells, or by inhibition of ERK and Akt in host endothelial cells. These demonstrate that attempts to interrupt the interaction of MSCs and cancer cells help to abrogate angiogenesis and inhibit tumor growth in tumors formed by cancer cells admixed with MSCs. These data demonstrate that the tumor microenvironment, namely, MSCs-secreted IL-6, may enrich the proangiognic factors secreted by cancer cells to increase angiogenesis and tumor growth and that targeting this interaction may lead to novel therapeutic and preventive strategies.
INTRODUCTION
Formation of vasculature or angiogenesis is actively involved in a wide variety of pathological events, including tumor development, progression and metastasis. The formation of blood vessels involves a series of events, including endothelial cells activation and proliferation, migration towards angiogenic stimuli, and the recruitment of perivascular support cells. 1 Contribution from diverse tissue-specific stem cell types to create the cell populations of tumor niche as well as the orchestrated communication between these cells and tumor cells are necessary for the activation of angiogenesis and neovascular formation. Tumor-associated stromal cells, such as immunologic cells and fibroblasts, have been implicated in the process. 2 There is also growing attention to the role of cells derived from bone marrow cells in tumor angiogenesis. 3 Mesenchymal stem cells (MSCs) are non-hematopoietic precursor cells residing in the bone marrow, which can contribute to the maintenance and regeneration of a variety of connective tissues. 4 These cells have attracted interest because they have been shown to home and contribute to the tumor microenvironment and also to influence tumor development, growth, progression, resistance to chemotherapy and metastasis in many solid cancers, such as those in the brain, breast and colon. 5 Karnoub et al. 6 demonstrated that MSCs mixed with weakly metastatic human breast carcinoma cells can enhance the metastasis ability, allowing the formation of a tumor xenograft via the CCL5/CCR5 axis. Patel et al. 7 discovered that MSCs protect breast cancer cells from immune clearance mediated by natural killer cells and cytotoxic T lymphocytes by secreting TGF-b1 to increase the regulatory T-cells number. In co-culture experiments, Lis et al. 8 showed that MSCs co-cultured with ovarian cancer cells can induce thermotolerant tumor cells in a CXCL12-dependant manner, and inhibition of CXCL12/CXCR4 pathway restored the cytotoxicity of hyperthermia in these cells Jeanine et al. 9 demonstrated that MSCs induce tumor resistance to chemotherapy through the release of platinum-induced fatty acids. Moreover, the ability of MSCs to enhance tumor growth was promoted by pretreatment with inflammatory factors such as interferon-g and tumor necrosis factor-a.
populations of cells. First, MSCs do not express several markers of CAFs, such as aSMA, PDGFRb and FSP1 until they are exposed to tumor cell-conditioned medium in vitro or tumor in vivo. 12, 13 Second, once MSCs are incorporated into tumor development they lose the potential to differentiate into mesenchymal tissues. 14 Most importantly, MSCs secrete CXCL12 to recruit endothelial cells only after exposure to a tumor. 13 These observations suggest MSCs do not use the same mechanisms of CAFs to interact with cancer cells in the earliest stage of xenograft tumor development. Moreover, whether or not MSCs are involved in the early processes of xenograft tumor development remains unclear.
Recently, we have demonstrated that MSCs within tumor cells secrete interleukin-6 (IL-6) to induce non-cancer stem cells to express markers of cancer stem cells and increase the ability to form a tumor in vivo, 14 suggesting the interaction of MSCs and cancer cells occurs very early in tumor formation. In the current study, we examined the interaction of MSCs and cancer cells during the early inoculation of both cells in vivo. We found that at the earliest stage of xenograft tumor formation MSC secretes IL-6 to induce the secretion of endothelin-1 (ET-1) by cancer cells, which then activates the Akt and ERK in endothelial cells, thereby recruiting endothelial cells to tumor development. Blocking of the interaction between MSCs-cancer cells-endothelial cells by anti-IL-6 antibodies, ET-1 inhibitor or specific inhibitors of Akt and ERK abrogated tumor angiogenesis, and thereby inhibited tumor growth.
RESULTS

MSCs promote tumor growth and angiogenesis in colorectal cancer
To investigate the functional consequences of the heterotypic interactions between HT-29 colorectal cancer cells and bone marrow-derived MSCs, the growth kinetics of the MSCs-containing tumors (HT-29 plus MSCs) were compared with those of HT-29 or MSCs alone in a xenograft model of immuno-compromised mice. To investigate the roles of MSCs in enhancing tumor growth rather than tumor formation, the experiments were performed with tumor cells at 10
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, with injection of this number tumor cells alone were able to form tumor. We found that co-injection with 10 5 MSCs increased the tumor growth rate, compared with injection with an equal number of HT-29 cells alone, while upto 10 6 of MSCs did not form tumors 6 months after transplantation alone ( Figure 1a) . The increased tumor growth due to co-injected MSCs occurred as early as at 1 to 2 weeks after injection, suggesting the interaction of MSCs and cancer cells occurred early in xenograft tumor formation in mice. Significantly, we also found that tumors formed by HT-29 cells admixed with MSCs also increased in blood vessel formation and capillary density both in gross and under microscopic analysis, compared with tumors formed by HT-29 alone (Figures 1b and c) . Moreover, MSCs-induced increase in the tumor growth rate and angiogenesis was more than that when mixed with CAFs or normal colonic fibroblasts (Figure 1 ). These data together suggest MSCs not only support tumor growth, but also enhance tumor angiogenesis.
MSCs promote colorectal cancer-induced endothelium recruitment and angiogenesis To further characterize the angiogenic effect of MSCs on HT-29 cells, we compared the rate of vessel formation of HT-29 and MSCs that were placed in the bottom of tubes that were then buried under the dorsal skin of immune-compromised mice. No vessel formation was found in empty tubes after two weeks, suggesting the tubes alone did not induce vessel formation (Figure 2a To investigate the signaling pathway that ET-1 activated to increase migration and tube formation in endothelial cells, we first checked Akt and ERK, which are known to be involved in endothelial migration and tube formation. 15 As expected, Akt and ERK were activated in endothelial cells when treated with CM from indirect co-culture of HT-29 and MSCs (Figure 5a) . Moreover, the activation of these pathways was inhibited in the presence of ET-1 specific antagonist (Figure 5b ). Blocking of ERK and Akt with specific inhibitors, PD98058 and LY294002, respectively, significantly blocked the activation of Akt and ERK, and the promotion of endothelial migration and tube formation by CM from indirect coculture of HT-29 and MSCs (Figures 5c-e) . These data suggest that the ET-1 secreted by HT-29 when co-cultured with MSCs activates ERK and Akt in endothelial cells and thereby promotes endothelial migration and angiogenesis.
IL-6 secreted by MSCs stimulated ET-1 production in cancer cells
To examine the molecular mechanism by which MSCs enhance secretion of ET-1 in HT-29, we noticed that the levels of CXCL1, IL-6 and IL-8 were not detected in HT-29 culture but were detected in MSC culture (Figure 6a ). Of these, IL-6 and IL-8 are associated with the angiogenesis in tumors. 16 Gene expression of CXCL1, IL-6 and IL-8 by MSCs, but not by HT-29, was first confirmed by analyzing the mRNA levels ( Figure 6a) . Significantly, treatment with IL-6, but not with IL-8 or CXCL1, enhanced ET-1 expression and secretion by HT-29 ( Figure 6b) . Similarly, IL-6 also enhanced ET-1 expression and secretion by CCS, HCW, COLO201 and HepG2 ( Supplementary Figures 2A and B) . Furthermore, CM derived from HT-29 that was treated with IL-6 enhanced both endothelial migration and tube formation (Figure 6c ). Similarly, Targeting the IL-6-ET-1 pathway abrogates MSCs-mediated promotion of tumor growth and angiogenesis To extend these findings in future clinical uses, we performed subcutaneous tube implantation using MSCs without or with IL-6 knockdown or treated with anti-IL-6 antibodies, or using HT-29 without or with ET-1 knockdown or treated with PD145065, PD98059 or LY294002. All of these inhibited vessel formation at 2 weeks compared with the control (Figures 7a and b) . Similar results were also observed when substituted HT-29 with other tumor cells (Supplementary Figure 3) . Consistently, we found that tumor growth and vessel formation in xenograft tumors were also enhanced when co-injected with these tumor cells together with MSCs, but not with MSCs with IL-6 knockdown or treated with anti-IL-6 antibodies, or using HT-29 with ET-1 knockdown or treated with PD145065 (Figure 7c ). The data presented here identify the relationship and signaling pathway in MSCs, tumor cells and endothelial cells, and also show how targeting the pathway (Figure 7d ) can help to develop methods in inhibiting tumor growth and angiogenesis.
MSCs promote growth and angiogenesis of tumors in tumor specimens To demonstrate the same relationship and signaling pathway in MSCs, tumor cells and endothelial cells in tumor, we performed immunostaining in xenograft tumor sections and patient tumor sections from three patients who received surgery for removal of their colorectal cancer. These data demonstrated the colocalization of CD44 (MSC marker) with IL-6, and CK20 (colorectal cancer marker) with ET-1 and found CD31 þ endothelial cells were very close to ET-1 immunostained areas in the xenograft tumor sections (Supplementary Figure 4) and the tumor specimen sections from all of the three patients (Supplementary Figure 5) . Moreover, we found CD31 þ endothelial cells were positive for pAKT and pERK (Supplementary Figures 4 and 5) . Together, these data suggest IL-6 is secreted by MSC-like cells to enhance ET-1 secretion in colorectal cancer cells and thereby activate and recruit endothelial cells to in vivo tumor growth areas. Tumor angiogenesis is important for tumor growth, especially when tumor diameter is greater than 7 mm. 18 Because of the difficulties in using models to observe cells or their interaction during early xenograft tumor development, the initial step of tumor angiogenesis and the involved components or cells are not yet well understood. In the current study, we used a unique angiogenesis in vivo model to investigate the interaction of tumor cells and MSCs and the role of this interaction in early tumor growth and angiogenesis. For this model, tumor cells, MSCs or their admixture were placed at the bottom of a 9 mm long silicone tube, above which growth factor reduced Matrigel was filled. The tube, with one end open, was implanted beneath mouse dorsal skin. This model provides a feasible system to observe angiogenesis, which requires endothelial cells to be recruited to the tube and pass the Matrigel. This allows the degree of angiogenesis to be compared. This model can also be applied to investigate the steps of tumor invasion and metastasis, to identify the detailed mechanisms under these phenomena, and to develop drugs for targeting the steps of tumor development, angiogenesis, growth, invasion and metastasis.
DISCUSSION
The roles of CAFs and other tumor niche cells in tumor development, angiogenesis, progression and metastasis have been thoroughly investigated in a variety of tumors including colorectal cancer. 19 For example, CAFs were found to be involved in tumor angiogenesis, resistance to chemotherapy, growth, progression, invasion and metastasis. CAFs make use of these properties by modulating the expression of oncogenic genes such as Her2, EGFR and Ras in cancer cells, thereby inducing their resistance to chemotherapy. 20 CAFs also secrete a panel of cytokine or growth factors such as CXCL1, CXCL2, IL-1b and IL-6 to enhance angiogenesis and tumor progression. 21 Recently, MSCs were found to home to tumors and transit into CAFs. 22, 23 The interaction of MSCs and tumor cells should happen at the very early stage of xenograft tumor development and growth, though the contribution of MSCs to these processes have not been well understood. We have previously demonstrated the contribution of MSCs to sites of tumor development as early as 3-4 days after tumor inoculation. 24 In the current study, we found that MSCs enhanced tumor angiogenesis within 14 days of tumor development. These data suggest that before tumor formation or the development of tumor niches such as formation of CAFs, the interaction of MSCs and tumor cells have already begun; and this has a great role in the consequent tumor angiogenesis, resistance to chemotherapy, growth, progression, invasion and metastasis.
Although MSCs have been reported to enhance tumor development, growth and progression, the roles of interaction between tumor cells and MSCs in the processes of tumor growth and angiogenesis have not been well studied. We have also demonstrated that MSCs secrete IL-6, which enhances tumor formation by increasing the amount of colorectal tumor initiation cells through the JAK2/STAT3 signal pathway. 14 In the current study we demonstrate that tumor cells have a baseline activity in enhancing angiogenesis, which can be enhanced by combining with MSCs. Thus, interaction with MSCs not only promotes tumor metastasis, dampens anti-tumor immunity, induces tumor initiation and reduces thermo-toxicity, but also enhances tumor angiogenesis. Although, CAFs have been demonstrated to enhance tumor growth and angiogenesis, however their effects on enhancing tumor growth and angiogenesis are ineffective when compared with MSCs. These data further suggest MSCs have a more important role in tumor growth and angiogenesis at the earliest stage of xenograft tumor development. These observations were more compatible to the fact that CAFs have not been developed early at tumor development.
MSCs have been demonstrated to increase tumor angiogenesis in solid cancers such as colon cancer. Lin et al. 10 demonstrated that MSCs when stimulated with interferon-g and tumor necrosis factor-a expressed higher levels of vascular endothelial growth factor via the HIF-1a pathway, thus increasing tumor angiogenesis and leading to colon cancer growth in mice. Coffelt et al. 25 reported that ovarian tumor cells secrete LL-37 to recruit MSCs, which serve as tumor stromal cells and secrete pro-angiogenic factors such as vascular endothelial growth factor and fibroblast growth factor-2. In the current study, we used an angiogenesis model to demonstrate that MSCs secreted IL-6, which induced the secretion of ET-1 by colorectal cancer cells, thereby recruiting endothelial cells to tumor and enhancing angiogenesis. By contrast, we did not find MSCs have a direct role in recruiting endothelial cells or enhancing angiogenesis. This discrepancy between the current study and previous ones may be due to the differences in the models or systems applied for investigation.
IL-6, which acts as both a pro-inflammatory and anti-inflammatory cytokine, has a critical role in tumor development and progression. Patients with colorectal cancer had significantly higher vascular endothelial growth factor and IL-6 levels than healthy controls, 26 suggesting IL-6 is involved in tumor development. ET-1, which acts as an autocrine/paracrine factor, is expressed and involved in tumor growth and progression in many types of cancers. 27 Though both IL-6 and ET-1 are important in tumor development, their relationship in tumors has not yet been clarified. To our knowledge this is first time that linkage of IL-6 with ET-1 in tumor cells has been shown to have an important role in tumor angiogenesis and growth. Thus it would be helpful to know whether the interaction of MSCs and tumor cells will also lead to increased survival, migration and metastasis, and tumor resistance in colorectal cancer.
There is a potential limitation of our experimental designs, as the subcutaneous region does not reflect the local microenvironment of orthotopic tumor growth in colorectal or hepatic tumor. We currently were unable to perform these experiments because the directed in vivo angiogenesis assay tubes used in current studies were too big to be placed in these regions. However, our studies in patient tumor specimen sections also revealed the same relationship and signaling pathway in MSCs, tumor cells and endothelial cells in tumor formation areas. Thus these data may reflect the involvement of MSCs and this pathway in tumor angiogenesis and growth in patients. Our in vivo angiogenesis model mimics the extremely restrictive environment of the early stage of xenograft tumor development, which can be applied to investigate the earliest stages in tumor formation and development such as angiogenesis. The model can also be modified to investigate the interaction of tumor cells with other tumor niche cells such as CAFs, TAMs, lymphocytes, pericytes cells, inflammatory cells or normal epithelial cells. The data presented here can help develop new strategies for targeting tumor angiogenesis and treating colorectal cancer.
MATERIALS AND METHODS
Primary cells and cell lines
HT-29 (human colorectal cancer cell line) was obtained from the ATCC and grown in DMEM-HG (Gibco, Grand Island, NY, USA) containing 1 Â penicillin/streptomycin, 4 mmol/l glutamine, and 10% fetal bovine serum (FBS; Gibco). Primary human MSCs were obtained from the Tulane Center for Distribution of Adult Stem Cells 28 and grown in a-MEM supplemented with 16.6% FBS (Gibco). The details about other cells were listed in Supplementary Table 1 . Cells were kept in 37 1C with 5% CO 2 .
Xenograft transplantation
Study protocols were approved by the Institutional Animal Committee of Taipei Veterans General Hospital. The athymic nude mice (BALB/cAnN. Cg-Foxn1nu/CrlNarl, National Laboratory Animal Center) were maintained in specific pathogen-free conditions. The mice were used for experiments at 6-8 weeks of age. Tumor cells admixed without/with MSCs were injected subcutaneously as was described further.
In vivo angiogenesis assay
Quantitative analysis of angiogenesis ability in colon cancer cells mixed with MSCs was performed using protocol modified from previously described directed in vivo angiogenesis assays. 29 Briefly, angioreactors were loaded with tumor cells or MSCs or their admixtures in the bottom, followed by filling with Cultrex (Matrigel prepared from EHS, phenol red-free, growth factor-reduced, Trevigen, Gaithersburg, MD, USA). The angioreactors were implanted subcutaneously into 6-to 8-week-old nude mice). Fourteen days after implantation, fluorescein isothiocyanate-labeled Griffonia lectin (FITC-lectin; Trevigen), an endothelial cell-selective reagent, was used to quantify invading endothelial cells into the angioreactor. Briefly, the directed in vivo angiogenesis assay angioreactor was collected from the mouse and the basement membrane extract mix recovered and digested with CellSperse (Trevigen) for 1 h at 37 1C. Cell pellets and insoluble fractions were collected by centrifugation at 1000 g for 10 min at room temperature, and washed three times with phosphate-buffered saline. After the last wash, the cell pellets were resuspended in 25 mg/ml FITC-lectin and incubated at 4 1C overnight. The stained pellets were centrifuged and washed with cold phosphate-buffered saline, and the final pellet was resuspended and relative fluorescence units determined in a spectrofluorometer (excitation 485 nm, emission 510 nm). The mean ± s.d. of RFU for three replicate assays was determined.
Cytokine array and enzyme-linked immunosorbent assay
Membranes from a human protein cytokine array kit and human angiogenesis array kit (Proteome Profiler Array; R&D, Minneapoils, MN, USA) were blocked with a blocking buffer and incubated with 1 ml of the concentrated condition medium at room temperature for overnight. The membranes were then washed with wash buffer, and assayed by chemiluminescence. To verify the results, the same samples were assayed with enzyme-linked immunosorbent assay kits for ET-1 and IL-6 (R&D).
Western blot
Cell extracts were prepared with M-PER (Pierce, Rockford, IL, USA) plus protease inhibitor cocktail (Halt; Pierce) and protein concentrations were determined using the bicinchoninic acid assay (BCA assay; Pierce). Aliquots of protein lysates were separated on SDS-10%-polyacrylamide gels and transferred to PVDF membrane filters, which were blocked with 5% blotting grade milk (Bio-Rad, Hercules, CA, USA) in TBST (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 1% Tween 20). Membranes were then probed with the indicated primary antibodies, reacted with corresponding secondary antibodies, and detected using a chemiluminescence assay (Millipore, Billerica, MA, USA). Membranes were exposed to X-ray film to visualize the bands (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Lentiviral vector production and cell infection
The expression plasmids and the bacteria clones for ET-1 shRNA (TRCN-0000003847, TRCN-0000003851 ) or IL-6 shRNA (TRCN-0000059203, TRCN-0000059207) were provided by the RNAi core of National Science Council in Taiwan. Lentiviral production was performed by transfection of 293 T cells using Lipofectamine 2000 (LF2000; Invitrogen, Carlsbad, CA, USA). Supernatants were collected 48 h after transfection and then were filtered. Subconfluent cells were infected with lentivirus in the presence of 8 mg/ml polybrene (Sigma-Aldrich, St Louis, MO, USA). At 24 h postinfection, we removed medium and replaced with fresh growth medium containing puromycin (1 g/ml) and selected for infected cells for 48 h.
Statistics
Data and results are reported as means ± s.d. Statistical comparisons between two groups were performed with unpaired Student's t-test.
ABBREVIATIONS
CAFs, cancer-associated fibroblasts; CM, conditioned medium; ET-1, endothelin-1; IL-6, interleukin-6; MSCs, mesenchymal stem cells; shRNA, short hairpin RNA.
